Corvus Pharmaceuticals Inc (NASDAQ:CRVS) Receives Consensus Rating of “Hold” from Brokerages

Shares of Corvus Pharmaceuticals Inc (NASDAQ:CRVS) have been given an average recommendation of “Hold” by the seven analysts that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $10.67.

Several equities research analysts recently weighed in on CRVS shares. Roth Capital started coverage on shares of Corvus Pharmaceuticals in a research report on Wednesday, May 29th. They set a “buy” rating and a $6.00 price target for the company. Zacks Investment Research raised shares of Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, July 15th.

In other Corvus Pharmaceuticals news, major shareholder Holdings A/S Novo sold 39,716 shares of Corvus Pharmaceuticals stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $5.32, for a total value of $211,289.12. Following the completion of the sale, the insider now owns 4,380,800 shares of the company’s stock, valued at approximately $23,305,856. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Richard A. Md Miller bought 7,500 shares of the business’s stock in a transaction on Wednesday, August 7th. The stock was bought at an average cost of $3.56 per share, with a total value of $26,700.00. The disclosure for this purchase can be found here. Insiders have purchased 880,690 shares of company stock valued at $3,223,227 in the last three months. 40.40% of the stock is owned by insiders.



A number of large investors have recently bought and sold shares of CRVS. Dimensional Fund Advisors LP grew its position in Corvus Pharmaceuticals by 29.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 336,327 shares of the company’s stock worth $1,234,000 after purchasing an additional 75,626 shares during the period. Geode Capital Management LLC grew its position in shares of Corvus Pharmaceuticals by 19.0% during the 4th quarter. Geode Capital Management LLC now owns 152,361 shares of the company’s stock valued at $559,000 after acquiring an additional 24,322 shares during the period. Two Sigma Investments LP bought a new stake in shares of Corvus Pharmaceuticals during the 4th quarter valued at $252,000. Bank of America Corp DE grew its position in shares of Corvus Pharmaceuticals by 32.0% during the 4th quarter. Bank of America Corp DE now owns 80,281 shares of the company’s stock valued at $294,000 after acquiring an additional 19,451 shares during the period. Finally, Squarepoint Ops LLC grew its position in shares of Corvus Pharmaceuticals by 44.5% during the 4th quarter. Squarepoint Ops LLC now owns 73,454 shares of the company’s stock valued at $270,000 after acquiring an additional 22,630 shares during the period. 84.19% of the stock is owned by institutional investors and hedge funds.

Shares of CRVS stock traded up $0.21 during trading hours on Friday, hitting $4.13. 5,197 shares of the company’s stock traded hands, compared to its average volume of 223,261. The stock has a fifty day moving average price of $4.77. Corvus Pharmaceuticals has a 12-month low of $3.22 and a 12-month high of $11.23. The company has a debt-to-equity ratio of 0.03, a quick ratio of 9.17 and a current ratio of 9.17.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.44) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.02). As a group, sell-side analysts forecast that Corvus Pharmaceuticals will post -1.59 earnings per share for the current fiscal year.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.

Further Reading: How much money do you need to begin day trading?

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.